taraxasterol has been researched along with Thyroid Neoplasms in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bai, Y; Han, P; Kou, B; Li, X; Liu, J; Wang, X; Xu, C; Yao, X; Zhang, S; Zhao, Q; Zheng, Z; Zhu, J | 1 |
1 other study(ies) available for taraxasterol and Thyroid Neoplasms
| Article | Year |
|---|---|
Taraxasterol inhibits TGF-β1-induced epithelial-to-mesenchymal transition in papillary thyroid cancer cells through regulating the Wnt/β-catenin signaling.
Topics: beta Catenin; Cell Line, Tumor; Cell Movement; Epithelial-Mesenchymal Transition; Humans; Matrix Metalloproteinase 2; Matrix Metalloproteinase 9; Neoplasm Invasiveness; Protease Inhibitors; Sterols; Thyroid Cancer, Papillary; Thyroid Neoplasms; Transforming Growth Factor beta1; Triterpenes; Wnt Signaling Pathway | 2021 |